Cardioversion for atrial fibrillation – how to prevent thromboembolic complications?

References

• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118:321–333.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
   PubMed Web of Science ®Google Scholar
• Wasmer K, Breithardt G, Eckardt L. The young patient with asymptomatic atrial fibrillation: What is the evidence to leave the arrhythmia untreated? Eur Heart J. 2014;35:1439–1447.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–2677.
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochr Database Sys Rev. 2015;CD005049. DOI:10.1002/14651858.CD005049.pub4
   Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840.
   PubMed Web of Science ®Google Scholar
• Airaksinen KEJ, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish Cardio Version) study. J Am Coll Cardiol. 2013;62:1187–1192.
   PubMed Web of Science ®Google Scholar
• Hellman T, Kiviniemi T, Nuotio I, et al. Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation. Thromb Res. 2017;156:163–167.
   PubMed Web of Science ®Google Scholar
• Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208–216.
   PubMed Web of Science ®Google Scholar
• Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19:851–855.
   PubMed Web of Science ®Google Scholar
• Palomäki A, Mustonen P, Hartikainen JEK, et al. Strokes after cardioversion of atrial fibrillation – the fibstroke study. Int J Cardiol. 2016;203:269–273.
   PubMed Web of Science ®Google Scholar
• Hinton RC, Kistler JP, Fallon JT, et al. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol. 1977;40:509–513.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003;111:137–142.
   PubMed Web of Science ®Google Scholar
• Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;63:493–505.
   Google Scholar
• Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001;37:1436–1442.
   PubMed Web of Science ®Google Scholar
• Freestone B, Chong AY, Lim HS, et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med. 2005;37:365–372.
   PubMed Web of Science ®Google Scholar
• Khan IA. Atrial stunning: basics and clinical considerations. Int J Cardiol. 2003;92:113–128.
   PubMed Web of Science ®Google Scholar
• Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359–1366.
   PubMed Web of Science ®Google Scholar
• Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol. 2013;61:852–860.
   PubMed Web of Science ®Google Scholar
• Sohara H, Amitani S, Kurose M, et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–112.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographics tudy. J Am Coll Cardiol. 1995;25:452–459.
   PubMed Web of Science ®Google Scholar
• Kleemann T, Becker T, Strauss M, et al. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation <48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22:1403–1408.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• Ryman J, Frick M, Frykman V, et al. Duration of warfarin sodium therapy prior to electrical cardioversion of atrial fibrillation. J Intern Med. 2003;253:76–80.
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346–3355.
   PubMed Web of Science ®Google Scholar
• Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388:1995–2003.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Pollack CV, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39:2959–2971.
   Web of Science ®Google Scholar
• Andò G, Trio O. New oral anticoagulants versus warfarin in patients undergoing cardioversion of atrial fibrillation. Int J Cardiol. 2016;225:244–246.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126:615–620.
   PubMed Web of Science ®Google Scholar
• Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40:926–933.
   PubMed Web of Science ®Google Scholar
• Stiell IG, Birnie D. Managing recent-onset atrial fibrillation in the emergency department. Ann Emerg Med. 2011;57:31–32.
   PubMedGoogle Scholar
• Burton JH, Vinson DR, Drummond K, et al. Electrical cardioversion of emergency department patients with atrial fibrillation. Anna Emerg Med. 2004;44:20–30.
   PubMed Web of Science ®Google Scholar
• Xavier Scheuermeyer F, Grafstein E, Stenstrom R, et al. Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med. 2010;17:408–415.
   PubMed Web of Science ®Google Scholar
• Stiell IG, Clement CM, Perry JJ, et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010;12:181–191.
   PubMedGoogle Scholar
• Michael JA, Stiell IG, Agarwal S, et al. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med. 1999;33:379–387.
   PubMed Web of Science ®Google Scholar
• Grönberg T, Hartikainen JEK, Nuotio I, et al. Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study). Am J Cardiol. 2016;117:1294–1298.
   PubMed Web of Science ®Google Scholar
• Nuotio I, Hartikainen JEK, Grönberg T, et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA - J Am Med Assoc. 2014;312:647–649.
   PubMed Web of Science ®Google Scholar
• Raiten JM, Ghadimi K, Augoustides JGT, et al. Atrial fibrillation after cardiac surgery: clinical update on mechanisms and prophylactic strategies. J Cardiothorac Vasc Anesth. 2015;29:806–816.
   PubMed Web of Science ®Google Scholar
• Kiviniemi T, Malmberg M, Biancari F, et al. Thromboembolisms related to post-operative electrical cardioversions for atrial fibrillation in patients with surgical aortic valve replacement. Eur Hear J – Qual Care Clin Outcomes. 2018;4:120–125.
   PubMed Web of Science ®Google Scholar
• Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016;374:1911–1921.
   PubMed Web of Science ®Google Scholar
• Grönberg T, Hartikainen JEK, Nuotio I, et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The finCV study. Pacing Clin Electrophysiol. 2015;38:368–375.
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lip GYH, Biancari F, et al. Predicting unsuccessful electrical cardioversion for acute atrial fibrillation (from the AF-CVS score). Am J Cardiol. 2017;119:749–752.
   PubMed Web of Science ®Google Scholar
• Hellman T, Kiviniemi T, Vasankari T, et al. Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study. BMC Cardiovasc Disord. 2017;17:33.
   PubMed Web of Science ®Google Scholar
• Hellman T, Kiviniemi T, Nuotio I, et al. Optimal timing for cardioversion in patients with atrial fibrillation. Clin Cardiol. 2018;41:966–971.
   PubMedGoogle Scholar
• Fumagalli S, Boncinelli L, Bondi E, et al. Does advanced age affect the immediate and long-term results of direct-current external cardioversion of atrial fibrillation? J Am Geriatr Soc. 2002;50:1192–1197.
   PubMed Web of Science ®Google Scholar
• Boriani G, Laroche C, Diemberger I, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF pilot general registry. Am J Med. 2015;128:509–518.e2.
   PubMed Web of Science ®Google Scholar
• Jaakkola J, Jaakkola S, Lahdenoja O, et al. Mobile phone detection of atrial fibrillation with mechanocardiography: the mode-AF study (mobile phone detection of atrial fibrillation). Circulation. 2018;137:1524–1527.
   PubMed Web of Science ®Google Scholar
• Freedman B. Screening for Atrial Fibrillation Using a Smartphone: Is There an App for That? [cited 2018 Jun 19]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015417/pdf/JAH3-5-e004000.pdf
   Google Scholar
• Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411–1420.
   PubMed Web of Science ®Google Scholar
• Seidl K, Rameken M, Drögemüller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion: final results of the Ludwigshafen observational cardioversion study. J Am Coll Cardiol. 2002;39:1436–1442.
   PubMed Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation. 2011;123:131–136.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Merino JL, Dan GA, et al. Relation of stroke and bleeding risk profiles to efficacy and safety of edoxaban for cardioversion of atrial fibrillation (from the Edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation [ENSURE-AF] study). Am J Cardiol. 2018;121:193–198.
   PubMed Web of Science ®Google Scholar
• Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82:1545–1547.
   PubMed Web of Science ®Google Scholar
• Hansen ML, Jepsen RMHG, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. EP Eur. 2015;17:18–23.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Lefèvre C, Collings S-L, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6:e011471.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Dell'Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014;35:1881–1887.
   PubMed Web of Science ®Google Scholar